Gastrointestinal cancers that once resisted checkpoint inhibitors are finally responding to novel combination strategies[1], with the FDA fast-tracking multiple targeted therapies designed to ...

A new AI tool is revolutionizing cancer treatment decisions by analyzing tissue images to predict tumor aggressiveness. This ...

Overcoming acquired treatment resistance is one of the major challenges in the fight against cancer. While combination ...

Dr Choo Mei Sze (PhD Development Psychology) is glowing. At 38, the mother-of-one still carries a fresh, youthful ...

The FDA's fast track designation acknowledges the combination's promising early efficacy and safety profile in treating MSS mCRC. Early data from a phase 1b/2 study showed deep, durable responses with ...

Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology ...

ORR achieved in second-line KRAS-mutant MSS colorectal cancer—triple historical response rates for Avastin + FOLFIRI of 6-11%Translational analysis shows pelareorep enhances KRAS-mutant–specific ...

Baystreet.ca News Commentary – The FDA issued multiple breakthrough approvals for oncology drugs in November 2025, marking a transformative month for cancer treatment with ...

Shares of Adagene Inc. (NASDAQ:ADAG) jumped more than 16% in pre-market trading on Tuesday after the biotech company said the ...

Oncolytics (ONCY) announced clinical and translational findings supporting the development of pelareorep in second-line metastatic colorectal ...

Cases of colorectal cancer in younger adults are climbing worldwide, driven by lifestyle changes and inherited genetic risks.

The results of the study could improve immunotherapy treatment for patients with colorectal and other barrier-tissue cancers.